- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: E 7080 | ER-203492-00 | Kisplyx® | Lenvima®
lenvatinib is an approved drug (FDA & EMA (2015))
Compound class: Synthetic organic
Comment: Lenvatinib is a potent inhibitor of VEGFR-2 (KDR) and VEGFR-3 (FLT4) .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: lenvatinib
1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J et al.. (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet, 391 (10126): 1163-1173. [PMID:29433850]
2. Musumeci F, Radi M, Brullo C, Schenone S. (2012)
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
J. Med. Chem., 55 (24): 10797-822. [PMID:23098265]